REFERENCES
- Sirotnak F.M., DeGraw J.I., Moccio D.M., Samuels L.L., Goutas L.J. New Folate Analogs of the 10-Deaza-aminopterin Series. Basis for Structural Design and Biochemical and Pharmacologic Properties. Cancer Chemother. Pharmacol. 1984; 12: 18–25
- Sirotnak F.M., DeGraw J.I., Schmid F.A., Goutas L.J., Moccio D.M. New Folate Analogs of the 10-Deaza-aminopterin Series. Further Evidence for Markedly Increased Antitumor Efficacy Compared with Methotrexate in Ascitic and Solid Murine Tumor Models. Cancer Chemother. Pharmacol. 1984; 12: 26–30
- Schmid F.A., Sirotnak F.M., Otter G.M., De Graw J.I. New Folate Analogs of the 10-Deaza-aminopterin Series: Markedly Increased Antitumor Activity of the 10-Ethyl Analog Compared to the Parent Compound and Methotrexate Against Some Human Tumor Xenografts in Nude Mice. Cancer Treat. Rep. 1985; 69(5)551–553
- Grant S.C., Kris M.G., Young C.W., Sirotnak F.M. Edatrexate, an Antifolate with Antitumor Activity: A Review. Cancer Investig. 1993; 11(1)36–45
- Kris M.G., Kinahan J.J., Gralla R.J., Fanuchi M.P., Wortheim M.S., O'Connell J.P., Marks L.D., William L., Farag F., Young C.W. Phase I Trial and Clinical Pharmacological Evaluation of 10-Ethyl-10-deazaaminopterin in Adult Patients with Advanced Cancer. Cancer Res. 1988; 48: 5573–5579
- Schornagel J.H., van der Vegt S., Verweij J., de Graeff A., Dullemond-Westland A., Van Deijk W.A., ten Bokkel Huinink W.W. Phase II Study of Edatrexate in Chemotherapy-Naive Patients with Metastatic Breast Cancer. Ann. Oncol. 1992; 3: 549–552
- Vandenberg T.A., Pritchard K.I., Eisenhauer E.A., Trudeau M.E., Norris B.D., Lopez P., Verma S.S., Buckman R.A., Muldal A. Phase II Study of Weekly Edatrexate as First-line Chemotherapy for Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. J. Clin. Oncol. 1993; 11(7)1241–1244
- D'Andrea G., Fennelly D., Norton L., Baselga J., Gilewsli T., Hudis C., Moynahan M.E., Raptis G., Skarin N., Surbone A., Theodolou M., Templeton M.A., Yao T.J., Seidman A.D. Phase I Study of Escalating Doses of Edatrexate in Combination with Paclitaxel in Patients with Metastatic Breast Cancer. Clin. Cancer Res. 1999; 5: 275–279